retatrutide dose clinical trials VisualAbstract: reduces body weight by 17.5% in patients with obesity Don't Make This Mistake with

S12, Feb

This includes trials of drug combinations such as Novo Nordisks CagriSema that combines semaglutide with investigational drug cagrilintide to improve efficacy

Adverse effects such as tachycardia, infections, headaches, dizziness, nausea, vomiting, diarrhea, and dyspepsia, as well as contraindications such as a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, hypersensitivity, severe gastrointestinal diseases, renal impairment, and pregnancy have been noted

Patients should maintain regular contact with their diabetes care team and report any concerns about hypoglycaemia, particularly if taking GLP-1 medications alongside other glucose-lowering agents such as sulphonylureas or insulin